Arca Biopharma, a clinical-stage biopharmaceutical company, has completed its merger with Oruka Therapeutics. The strategic move aims to leverage the strengths of both firms in the development and commercialization of innovative therapies. The merger is expected to create synergies by combining Arca Biopharma’s expertise in cardiovascular treatments with Oruka Therapeutics’ focus on oncology and central nervous system disorders. The newly formed entity aims to accelerate its pipeline development and expand its market reach.
Biopharmaceuticals, Healthcare, Mergers & Acquisitions,United States
https://mergersacquisitions.einnews.com/article/739615396/u2-z1fPYV_9mS_eb?ref=rss&ecode=Q1vNcweEggLWKz7L